Aclarion, Inc. Files 8-K on Shareholder Votes
Ticker: ACONW · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1635077
| Field | Detail |
|---|---|
| Company | Aclarion, INC. (ACONW) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing-update
Related Tickers: ACON
TL;DR
Aclarion (ACON) filed an 8-K on shareholder votes as of year-end 2024.
AI Summary
Aclarion, Inc. filed an 8-K on January 3, 2025, reporting on matters submitted to a vote of security holders as of December 31, 2024. The filing details the company's common stock and warrants, with its principal executive offices located in Broomfield, Colorado.
Why It Matters
This filing indicates Aclarion, Inc. is engaging in corporate governance activities, specifically related to shareholder voting, which can impact company direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- Aclarion, Inc. (company) — Registrant
- January 3, 2025 (date) — Filing Date
- December 31, 2024 (date) — Period of Report
- Broomfield, Colorado (location) — Principal Executive Offices
- Nocimed, Inc. (company) — Former Company Name
FAQ
What specific matters were submitted to a vote of Aclarion, Inc.'s security holders?
The filing states it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters in the provided text.
When was the period of report for the matters submitted to a vote?
The period of report for the matters submitted to a vote was as of December 31, 2024.
What is Aclarion, Inc.'s IRS Employer Identification Number?
Aclarion, Inc.'s IRS Employer Identification Number is 47-3324725.
Where are Aclarion, Inc.'s principal executive offices located?
Aclarion, Inc.'s principal executive offices are located at 8181 Arista Place, Suite 100, Broomfield, Colorado 80021.
What was Aclarion, Inc.'s former company name?
Aclarion, Inc.'s former company name was Nocimed, Inc., with a date of name change on February 26, 2015.
Filing Stats: 658 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2025-01-03 14:49:18
Filing Documents
- acon_8k.htm (8-K) — 54KB
- 0001683168-25-000056.txt ( ) — 274KB
- acon-20241231.xsd (EX-101.SCH) — 4KB
- acon-20241231_def.xml (EX-101.DEF) — 29KB
- acon-20241231_lab.xml (EX-101.LAB) — 36KB
- acon-20241231_pre.xml (EX-101.PRE) — 26KB
- acon_8k_htm.xml (XML) — 6KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On December 31, 2024, the Company held its 2024 Annual Meeting of Stockholders. The matters voted upon at the Annual Meeting and the results of such voting are set forth below. Proposal 1 - Election of seven directors to serve a term ending at the 2024 annual meeting, in each case until their respective successors are duly elected and qualified. Nominee Votes For Withheld Broker Non-Votes Jeffrey Thramann 1,189,506 107,489 2,741,544 Brent Ness 1,191,173 105,822 2,741,544 Stephen Deitsch 1,190,745 106,250 2,741,544 Scott Breidbart 1,190,700 106,295 2,741,544 David Neal 1,191,463 105,532 2,741,544 William Wesemann 1,190,739 106,256 2,741,544 Amanda William 1,189,744 107,251 2,741,544 All seven director nominees were duly elected. Proposal 2 - Ratification of appointment of independent registered accounting firm – Haynie & Company Votes For Votes Against Abstain Broker Non-Votes 3,776,879 250,987 10,673 0 Proposal 2 was approved. Proposal 3 – Approval of the issuance of shares pursuant to the Company's equity line Votes For Votes Against Abstain Broker Non-Votes 1,129,322 164,731 2,941 2,741,545 Proposal 3 was approved. Proposal 4 – Approval of the issuance of shares pursuant to the Company's Series B convertible preferred stock Votes For Votes Against Abstain Broker Non-Votes 1,126,568 167,172 3,254 2,741,545 Proposal 4 was approved. 2 Proposal 5 – Approval of the issuance of shares pursuant to the Company's Series C convertible preferred stock and related warrants Votes For Votes Against Abstain Broker Non-Votes 1,119,622 174,470 2,902 2,741,545 Proposal 5 was approved. Proposal 6 – Approval of a proposed reverse stock split Votes For Votes Against Abstain Broker Non-Votes 3,006,776 1,016,688 15,072 0 Proposal 6 was approved. Proposal 7 –
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARION, INC. January 3, 2025 By: /s/ John Lorbiecki Name: John Lorbiecki Title: Chief Financial Officer 4